comparemela.com

Latest Breaking News On - Mrna impfstoffe - Page 1 : comparemela.com

BioNTech Announces Strategic Partnership with UK Government

Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in.

United kingdomUnited statesCity ofUgur sahinUnited kingdom researchEuropean unionCompany fixvacNational health serviceUnited kingdom governmentChief executive officerIntellectual propertyNasdaq bntxBiontech seUk governmentCancer vaccineMrna vaccine

BioNTech Initiates Phase 1 Clinical Trial for Malaria

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate.

United statesSylke maasFosun pharmaWorld health organizationRoche groupAfrica centers for diseaseCompany malariaAfrica centersDisease controlChief medical officerNew technologiesPrivate securities litigation reform actQuarterly reportNasdaq bntxBiontech seMrna vaccine

Update on First BioNTainer for African-based mRNA

MAINZ, GERMANY, December 21, 2022 BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable mRNA vaccine.

South africaSylke maasFosun pharmaVp corporate communicationsAfrican unionRoche groupNew technologiesPrivate securities litigation reform actQuarterly reportNasdaq bntxBiontech seAfrican unionRna productionRna vaccinesFrikanische unionRna produktion

BioNTech Expands Global Footprint by Acquiring GMP

First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based.

Sylke maasSierk poettingFosun pharmaSingapore economic development boardBiontech pharmaceuticals asia pacific pteRoche groupAsia pacificPharmaceuticals asia pacificNovartis singapore pharmaceutical manufacturingRegional headquartersChief operating officerGoh wan yeeSenior vice presidentNew technologiesPrivate securities litigation reform actQuarterly report

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With

NEW YORK and MAINZ, Germany, July 27, 2022 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a.

United statesUnited kingdomSylke maasFosun pharmaCenters for diseaseDrug administrationExchange commissionPfizer incEuropean unionRoche groupMarketing authorization holderEmergency use authorizationCoronavirus diseaseDisease controlVaccine adverse event reporting systemFact sheets

vimarsana © 2020. All Rights Reserved.